Five genes showed a significantly better OS in GC patients when upregulated, (SLC30A1: HR 0.62 [95% CI 0.5–0.76], P = 9.1e−06; SLC30A5: HR 0.6 [95% CI 0.47–0.76], P = 2.5e−05; SLC30A6: HR 0.61 [95% CI 0.49–0.79], P = 8.6e−06; SLC30A7: HR 0.62 [95% CI 0.49–0.78], P = 4.2e−05; and SLC30A9: HR 0.52, [95% CI 0.44–0.62], P = 2.5e−13). This evidence concerns the gene SLC30A6 and gastric cancer.